论文部分内容阅读
目的观察拉米夫定联合阿德福韦酯治疗慢性乙型肝炎(CHB)的疗效。方法CHB患者210例,随机分为对照组、观察组,各105例。两组均接受护肝、对症支持治疗,对照组在此基础上给予拉米夫定,观察组在此基础上给予拉米夫定及阿德福韦酯,疗程均为48周。检测两组治疗前后HBV DNA定量及肝功能指标(ALT、AST、TBIL、DBIL)。采用SPSS19.0统计软件。计量资料采用(xˉ±s)表示,组间比较采用U检验。P<0.05为差异有统计学意义。结果治疗前观察组、对照组HBV DNA定量检测结果分别为(7.71±0.83)、(7.65±0.80)log copies/ml,差异无统计学意义(P>0.05)。治疗48周后,观察组、对照组HBV DNA定量检测结果分别为(2.79±0.25)、(3.52±0.37)log copies/ml,差异有统计学意义(P<0.05)。观察组、对照组治疗前后组内HBV DNA定量比较,差异均有统计学意义(均P<0.05)。治疗前两组ALT、AST、TBIL、DBIL相比差异均无统计学意义(均P>0.05);治疗48周后,观察组ALT、AST、TBIL、DBIL显著低于对照组(均P<0.05)。结论与单独应用拉米夫定相比,拉米夫定联合阿德福韦酯治疗CHB疗效更好。
Objective To observe the curative effect of lamivudine combined with adefovir dipivoxil on chronic hepatitis B (CHB). Methods 210 CHB patients were randomly divided into control group, observation group, 105 cases each. Both groups received liver protection and symptomatic supportive treatment. The control group received lamivudine on the basis of this treatment. The observation group was given lamivudine and adefovir dipivoxil on the basis of the above treatment, both for 48 weeks. HBV DNA and liver function indexes (ALT, AST, TBIL, DBIL) before and after treatment were detected. Using SPSS19.0 statistical software. Measurement data using (xˉ ± s), said comparison between groups using U test. P <0.05 for the difference was statistically significant. Results Before treatment, the quantitative detection of HBV DNA in the observation group and the control group were (7.71 ± 0.83) and (7.65 ± 0.80) log copies / ml, respectively, with no significant difference (P> 0.05). After 48 weeks of treatment, the quantitative detection results of HBV DNA in the observation group and the control group were (2.79 ± 0.25) and (3.52 ± 0.37) log copies / ml, respectively, with statistical significance (P <0.05). The levels of HBV DNA in observation group and control group before and after treatment were significantly different (all P <0.05). There was no significant difference in ALT, AST, TBIL and DBIL between the two groups before treatment (all P> 0.05); after treatment for 48 weeks, ALT, AST, TBIL and DBIL in the observation group were significantly lower than those in the control group ). Conclusion Compared with lamivudine alone, lamivudine combined with adefovir dipivoxil treatment of CHB better.